Avalo Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Avalo Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2023.
  • Avalo Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.9M, a 243% decline year-over-year.
  • Avalo Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$62.9M, a 120% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$27.4M, a 26.9% increase from 2022.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$37.4M, a 54.4% increase from 2021.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$82.1M, a 12.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$27.4M +$10.1M +26.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$37.4M +$44.7M +54.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$82.1M -$9.29M -12.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 -$72.8M -$56.7M -351% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-02
2019 -$16.1M +$19.2M +54.4% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-08
2018 -$35.4M -$49.3M -355% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 $13.9M +$30M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-18
2016 -$16.1M -$5.07M -46.1% Jan 1, 2016 Dec 31, 2016 10-K 2018-04-02
2015 -$11M +$6.11M +35.7% Jan 1, 2015 Dec 31, 2015 10-K 2018-04-02
2014 -$17.1M -$4.18M -32.3% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-14
2013 -$12.9M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.